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Background and Objectives. We compared the effi-
cacy and safety of low molecular weight heparins
(LMWH) and unfractionated heparin (UFH) in the
treatment of deep venous thrombosis (DVT). A com-
parison between two daily subcutaneous injections of
LMWH against a single injection was also performed.
Design and Methods. The study was performed by a
meta-analysis. Clot improvement in venography,
recurrency, total mortality and major hemorrhages
were assessed in 4,472 patients with DVT from 21
studies treated with subcutaneous LMWH or UFH.
Results. An improvement in clot reduction (odds
ratio 0.73, 95% confidence interval 0.59 to 0.90, p
= 0.004), a decrease in total mortality (0.68, 0.50 to
0.91, p = 0.012) and a lower incidence of hemor-
rhage (0.65, 0.43 to 0.98, p = 0.047) were observed
in LMWH treated patients. There were no differences
in recurrences (0.78, 0.59 to 1.04, p = 0.10). A sin-
gle dose of LMWH was better than two in reducing
major bleeding (χ2 = 4.99, p = 0.025); however, the
two dose regimen was more effective in clot reduc-
tion (χ2 = 8.56, p = 0.004).
Interpretation and Conclusions. LMWH is superior to
UFH in terms of safety and efficacy. A single daily
dose of LMWH dose is a suitable therapeutic regi-
men and could facilitate the outpatient treatment of
venous thromboembolism. 
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it can lead to valvular damage and chronic venous
insufficiency in subsequent years and in rare cases
to an immediate threat to life from pulmonary
embolism (PE) due to displacement of the throm-
bus.5 So, nowadays DVT and PE are considered as
the expression of one and the same disease, termed
venous thromboembolism (VTE).
Although anticoagulant therapy is the treatment of
choice for most patients with VTE, the establishment
of a treatment strategy is difficult because the opti-
mum use of this treatment remains to be defined. In
this setting, many regimes have been tested over the
last decades including the use of oral anticoagulants,
antithrombotic drugs, unfractionated heparin (UFH)
and aspirin.
In recent years low molecular weight heparins
(LMWH) have become available as alternatives to
oral anticoagulants and unfractionated heparin for
the treatment of VTE. LMWH are derived by con-
trolled chemical or enzymatic depolymerization of
standard UFH that yield chains with a mean molec-
ular weight of about 5,000.6 These heparin mole-
cules with a lower molecular weight inhibit activat-
ed coagulation factor Xa more efficiently than they
inhibit thrombin because the length of the LMWH
does not allow binding to both thrombin and
antithrombin III. LMWH have several advantages
over UFH based on their high bioavailability and
more consistent anticoagulant effect at therapeutic
doses, thus enabling them to be administered in
fixed doses as a twice or single daily injection with-
out the need for laboratory monitoring.7,8 Further-
more, for an equivalent antithrombotic effect,
LMWH are thought to be less likely to cause hemor-
rhage with a reduced risk of bleeding, especially in
surgical patients during the perioperative period.9
Some randomized clinical trials have been reported
which compare LMWH with UFH in the treatment of
DVT showing that LMWH can significantly decrease
the risk of recurrence and mortality with minor risk of
hemorrhagic events.10,11 However, most of the pub-
lished works showed no statistically significant differ-
ences. Assuming an α risk of 0.05 and an expected
incidence of events similar to the average of published
trials, the number of patients needed in a single trial
in order to achieve a statistical power of 80% would
be approximately as follows: 2,350 patients for com-
paring the risk of clot impairment, 4,620 for total
mortality, 8,520 for major bleeding and 11,500 for
recurrences. The magnitude of these figures has
Deep vein thrombosis (DVT) is a commoncomplication in patients suffering from a widevariety of processes such as malignancy,
spinal injuries, advanced age, and hypercoagulabil-
ity syndromes as well as in patients subjected to
major orthopedic or general surgery1-3 with an inci-
dence as high as 50% in patient groups not under
thromboprophylaxis treatment.4 Although in many
cases DVT resolves without sequelae, in some cases
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encouraged some researchers to perform meta-analy-
ses in order to achieve definitive conclusions.12-16
Unfortunately, these meta-analyses have not yielded
homogeneous results. This could partially be explained
by the relatively small number of patients included in
these studies (Table 1).
The present study was designed to assess the effec-
tiveness and safety of UFH and LMWH in the treat-
ment of VTE by means of a meta-analysis, taking into
account the most recent studies, which were not
included in any previous compilatory study , thus
enhancing its analytic power. Furthermore, treatment
with two daily subcutaneous injections of LMWH
was compared to a single injection with regard to
immediate and long term efficacy and side effects.
Design and Methods
Data collection
We performed a MEDLINE search of the literature
between January 1985 and June 1999 with no restric-
tion on the language of the paper using the follow-
ing combined key words: low molecular weight
heparin (LMWH) and thromboembolic disease;
LMWH and deep vein thrombosis; LMWH and treat-
ment; LMWH and clinical trial*; LMWH and meta-
analysis; LMWH and review. A search in the Excerp-
ta Medica, in abstracts books of meetings of the Inter-
national Society of Thrombosis and Hemostasis and in the
Table 1. Summary of individual trial designs.
Sample size LMWH Route of 
Study (LMWH/UFH) used administration
LMWH UFH
Bratt et al., 198524 25/29 Dalteparin i.v. (sdd) i.v.
Holm et al., 198625 29/27 Dalteparin s.c. (tdd) s.c.
Faivre et al., 198826 33/37 CY 222 s.c. (tdd) s.c.
Notarbartolo et al., 198827 60/30 OP 2123 s.c. (sdd) s.c.
Zanghi et al., 198828 40/40 OP 2123 s.c. (sdd) s.c.
Albada et al., 198929 96/98 Dalteparin i.v. (sdd) i.v.
Etude Mult. FranVaise, 198930 33/33 Dalteparin s.c. (tdd) i.v.
Bratt et al., 199031 60/60 Dalteparin s.c. (tdd) i.v.
Harenberg et al., 199032 24/26 Certoparin s.c. (tdd) i.v.
Duroux, 199133 85/81 Nadroparin s.c. (tdd) i.v.
Prandoni et al., 199234 85/85 Nadroparin s.c. (tdd) i.v.
Lopaciuk et al., 199235 74/72 Nadroparin s.c. (tdd) s.c.
Hull et al., 199211 213/219 Logiparin s.c. (sdd) i.v.
Simonneau et al., 199310 67/67 Enoxaparin s.c. (tdd) i.v.
Tedoldi et al., 199336 20/20 OP 2123 s.c. (sdd) s.c.
Lindmarker et al., 199437 101/103 Dalteparin s.c. (sdd) i.v.
Luomanmaki et al., 199638 110/116 Dalteparin s.c. (sdd) i.v.
Fiessinger et al., 199639 120/133 Dalteparin s.c. (sdd) i.v.
Levine et al., 199640 247/253 Enoxaparin s.c. (tdd) i.v.
Koopman et al., 199641 202/198 Nadroparin s.c. (tdd) i.v.
Columbus Investigators, 199742 510/511 Reviparin s.c. (tdd) i.v.
LMWH: low molecular weight heparin; UFH: unfractionated heparin; i.v.: intra-
venous; s.c.: subcutaneous; sdd: single dose/day; tdd: two doses/day.
Table 2. Summary of individual trial results.
Phlebography
Clot reduction Clot extension Recurrent event Total mortality Major bleeding
LMWH UFH LMWH UFH LMWH UFH LMWH UFH LMWH UFH
Study E/Pts E/Pts E/Pts E/Pts E/Pts E/Pts E/Pts E/Pts E/Pts E/Pts
Bratt et al., 198524 16/25 14/29 0/25 3/29 0/25 0/29 0/25 0/29 2/13 0/14
Holm et al., 198625 10/25 12/25 1/25 2/25 1/29 0/27 0/29 0/27 0/27 0/28
Faivre et al., 198826 19/30 19/29 0/30 2/29 1/33 1/37 0/33 1/37 0/33 0/35
Notarbartolo et al., 198827 - - - 0/60 0/30 0/60 0/30 0/60 3/30
Zanghi et al., 198828 - - - - 0/40 0/40 0/40 0/40 0/40 0/40
Albada et al., 198929 - - - - 0/96 1/98 0/96 2/98 10/96 13/98
Etude Mult. FranVaise, 198930 - - 1/33 2/33 0/33 0/33 0/33 0/33 0/33 0/33
Bratt et al., 199031 34/45 30/49 2/45 3/9 4/60 6/60 0/60 0/60 0/55 2/55
Harenberg et al., 199032 13/15 10/13 1/15 0/13 2/24 2/26 - - 2/24 1/26
Duroux, 199133 54/77 44/71 5/77 5/71 1/85 2/81 3/78 3/73 2/85 4/81
Prandoni et al., 199234 50/83 36/85 5/83 14/85 6/85 12/85 5/85 9/85 1/85 3/85
Lopaciuk et al., 199235 45/68 32/68 10/68 12/68 0/74 3/72 0/74 1/72 0/74 1/72
Hull et al., 199211 - - - - 6/213 15/219 10/213 21/219 1/213 11/219
Simonneau et al., 199310 35/60 18/57 1/60 5/57 1/67 7/67 3/67 2/67 0/67 0/67
Tedoldi et al., 199336 - - - - 0/20 1/20 0/20 0/20 0/20 0/20
Lindmarker et al., 199437 55/91 56/89 5/91 7/89 5/101 3/103 2/101 3/103 0/101 0/103
Luomanmaki et al., 199638 47/92 61/98 11/92 7/98 5/110 2/116 - - 0/110 1/116
Fiessinger et al., 199639 65/96 62/103 8/96 12/103 6/111 3/120 2/111 4/120 0/120 2/133
Levine et al., 199640 - - - - 13/247 17/253 11/247 19/253 5/247 3/253
Koopman et al., 199641 - - - - 14/202 17/198 4/202 7/198 1/202 4/198
Columbus Investigators, 199742 - - - - 27/510 25/511 36/510 39/511 16/510 12/511
Total events/pts, 443/707 394/716 50/740 74/749 93/2,225 117/2,225 76/2084 111/2075 40/2215 60/2217
(%) (62.6) (55.0) (6.75) (9.87) (4.13) (5.25) (3.64) (5.34) (1.80) (2.70)
LMWH: low molecular weight heparin; UFH: unfractionated heparin; E/pts: events/patients.
references lists of review and trials papers was also
performed to avoid omission of papers that might
not have been included in the MEDLINE database.
We excluded non-randomized trials, and we also
excluded those which were duplicate reports of data
previously published.
Information was extracted from studies to assess
the following issues:
- proportion of patients with any degree of impair-
ment in the venogram, if pre- and post-treatment
evaluations (by phlebography) were done and the
assessment was masked with respect to treatment
assignment;
- number of patients in each group developing recur-
rent thromboembolic events (symptomatic recur-
rent DVT or PE) during the trial period, if reliable
diagnostic criteria were used for recurrent throm-
boembolism, if active follow-up was done prospec-
tively at each center, and if the assessment was
masked to treatment assignment. The diagnosis of
DVT was accepted if one of the following criteria
was met:
A) a new constant intraluminal filling defect not
present on the last available venogram; or
B) if the venogram was not diagnostic, either an
ultrasound result that had been normal before
the suspected episode.17
A diagnosis of PE was considered valid if one of
the following criteria was met:
A) a segmental defect on the perfusion lung scan.
B) positive pulmonary angiography or
C) PE at autopsy;
- total mortality at the end of follow-up was col-
lected from each report, if any monitoring system
for active follow-up was prospectively performed
by the researchers;
- the number of patients who presented major hem-
orrhages during the treatment was also included as
an end-point to assess safety. Hemorrhages were
considered major if they were fatal, or if any trans-
fusion was needed or they led to the interruption
of treatment. In addition all bleeding inside the
brain or into the peritoneum was also considered
as a major event. All other hemorrhages were con-
sidered as minor and were not included as end-
points.
Statistical methods
The risks of an impairment in phlebography, suf-
fering recurrent thromboembolic events, death from
any cause, and major hemorrhages in patients treat-
ed with LMWH and patients treated with UFH were
compared by calculation of the odds ratio (OR) for
each study. These ORs were pooled across studies
using the Mantel-Haenszel method to estimate a
common OR as an estimator of relative risk (RR).
Then 95% confidence intervals (CI) were computed
for the common RR using the Mantel-Haenszel
method.18,19 In addition, the analysis was repeated
using a random effect model according to Der
Simionian and Laird.20 ORs were also calculated with
the same methodology to compare the risk of an
impairment in phlebography, developing recurrent
thromboembolic events, major hemorrhages and
death stratifying the studies into two groups: those
which used two doses of LMWH and those which
used a single dose; the comparison group was UFH
for both strata. The Schlessemann chi squared test
was used to compare the ORs between both strata.21
We also estimated  the number of patients needed
to be treated using the incidence of events in the UFH
group as the reference and applying the ORs provid-
ed by the meta-analyses.22,23
Results
Comparison between LMWH and UFH
Overall 21 randomized studies10,11,24-42 comparing
the efficacy of LMWH with that of UFH in a total of
4,472 patients were identified. In 15 trials the UFH
was given intravenously (i.v.); subcutaneous (s.c.)
injection was used in the remaining 6 studies. The
patients in the LMWH groups received dalteparin in 8
trials [2 i.v., 3 s.c. at a single dose/day (sdd), 3 s.c. at
two doses/day (tdd)], nadroparin in 4 trials (s.c., tdd),
OP 2,123 in 3 trials (s.c., sdd), enoxaparin in 2 trials
(s.c., tdd), CY 222 (s.c., tdd), certoparin (s.c., tdd),
logiparin (s.c., sdd) and reviparin (s.c., tdd) in one tri-
al. Each trial’s design and results are summarized in
Tables 1 and 2, respectively. In addition, pooled
results of main end-points are given as unadjusted
incidences and in terms of odds reduction as well.
Clot reduction in venography. In 13 studies (diagnosis
confirmed by phlebography), the unadjusted overall
improvement in venography was 55% (394 out of 716
patients) in the UFH group compared with 62.7% (443
out of 707 patients) in the LMWH group. An impair-
ment was assessed in 9.9% of the UFH-treated patients
compared with in 6.7% in the LMWH group (Figure
1). The results from four of the studies11, 33-35 showed a
significant improvement in clot reduction in favor of
LMWH and the results from the meta-analysis (fixed
effects model) for this end-point showed that LMWH
is significantly more efficient than UFH in terms of
reducing thrombus extension [27% reduction, OR
937
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Figure 1. Crude overall incidence of major end-points
assessed in the meta-analysis. Number of events/total
patient numbers given in parentheses for each end-point.
LMWH: low molecular weight heparin; UFH: unfractionated
heparin.
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0.73; 95% CI, 0.59 to 0.90; p = 0.004 (Figure 2)]. The
random effects model showed very similar results. The
number of patients needed to switch from UFH to
LMWH in order to achieve improvement in one venog-
raphy would be 13 (95% CI: 8-40).
Incidence of recurrent thromboembolism. The unadjust-
ed overall incidence rates for recurrent thromboem-
bolic events were 5.2% (117 out of 2,225 patients) in
the UFH group, and 4.1% (92 out of 2,225 patients)
in the LMWH group (Figure 1). When taken sepa-
rately, only one of the studies11 showed a statistical-
ly significant difference between both treatments. The
results from the meta-analysis (Mantel-Haenszel
method) showed a near to significant statistical asso-
ciation with a 22% reduction in the recurrence of
thromboembolism in favor of the LMWH group [OR
0.78; 95% CI, 0.59 to 1.04; p = 0.103 (Figure 3)].
Results with the Der Simonian and Laird method
were again very similar (OR = 0.814; 95% CI, 0.61 to
1.08).
Total mortality. The unadjusted overall total mor-
tality was higher in the UFH patients (111 out of
2,075, 5.3%) than in the LMWH group (76 out of
2,084, 3.6%) (Figure 1). When taken separately, only
one of the studies10 showed statistically significant
differences between both treatments. However, the
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Figure 2. Results from meta-analysis (fixed effects model,
Mantel-Haenszel method) for efficacy of treatment evaluat-
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Figure 3. Results from meta-analysis (fixed effects model)
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Figure 5. Results from meta-analysis (fixed effects model)
for safety of treatments evaluated by analyzing the inci-
dence of major hemorrhagic events. Results for each trial
given; global results shown at bottom. Odds ratio <1 indi-
cates that low molecular weight heparins did better than
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results from the meta-analysis showed a significant
33% reduction in the total mortality rate in favor of
the LMWH group [OR 0.68; 95% CI, 0.50 to 0.91; p
= 0.012 (Figure 4)].
Safety and hemorrhagic events. The unadjusted overall
incidence of major bleeding was higher in the patients
receiving UFH (60 out of 2,217, 2.7%) than in the
patients assigned to LMWH (40 out of 2,215, 1.8%)
(Figure 1). Only one of the individual studies10
showed significant differences between both treat-
ments. However, the fixed-effects meta-analysis again
showed that the risk of major hemorrhage decreased
significantly in the LMWH group [35% reduction, OR
0.65; 95% CI, 0.43 to 0.98; p = 0.047 (Figure 5)].
This was also true for the random-effects model. The
number of patients needed to switch from UFH to
LMWH in order to prevent one episode of severe
bleeding would be 106 (95% CI: 55-1,294).
Comparison between LMWH administered as
two doses and LMWH administered in a single
dose
Table 3 summarizes the results obtained when we
calculated the ORs comparing LMWH and UFH sep-
arately in two strata depending on whether one or
two doses of LMWH were used. The Schlessemann
chi squared test for comparisons between ORs was
also computed to establish the comparison between
both patterns of administering LMWH and UFH. The
two doses per day route exhibited a lower OR when
compared with UFH and therefore seemed to be
more effective than the single dose in terms of pre-
venting thrombus extension (χ2 = 8.56, p = 0.004). In
fact, LMWH in a single dose was not significantly
more effective than UFH in reducing the clot size as
the 95% CI for the OR ranged from 0.77 to 1.51
whereas it ranged from 0.42 to 0.74 in favor of
LMWH in two doses when this pattern was com-
pared with UFH. However, the administration of
LMWH in a single dose was more effective than the
two dose regime in reducing the risk of major bleed-
ing (χ2 = 4.99, p = 0.025). In this case two doses of
LMWM per day was not able to reduce the risk of
major hemorrhages with respect to UFH (95% CI,
0.47 to 1.32) whereas administered as a single dose,
LMWH was clearly safer than UFH (95% CI, 0.01 to
0.54). When analyzing the recurrency of throm-
boembolic events, there were no significant differ-
ences between both patterns of administration of
LMWH or between either of them taken separately
with respect to UFH, although LMWH given as two
doses was almost significantly more effective than
UFH (95% CI, 0.54 to 1.02). Finally, there were no
differences between the two ways of administering
LMWH in terms of total mortality. However, where-
as a single dose of LMWH was significantly better
than UFH in terms of total mortality (95% CI, 0.26 to
0.96), LMWH in two doses, although still better than
UFH, was not so to a degree to reach statistical sig-
nificance (95% CI, 0.53 to 1.04).
Discussion
Heparin has been the gold standard for the treat-
ment and prophylaxis of venous thrombosis for the
past fifty years.43,44 During the eighties LMWH under-
went extensive evaluation in clinical trials, mainly in
those evaluating the prevention of VTE in high-risk
patients.7,45-49 The high effectiveness of LMWH when
compared with UFH in the prevention of venous
thrombosis in patients undergoing major surgery, in
patients with spinal injury, and in patients with stroke
shown in these randomized studies led physicians to
modify the thromboprophylactic regimen in these
patients. In the last decade studies on LMWH have
focused on the comparison between these agents
and UFH in the treatment of established VTE. There
is currently accumulating evidence that these new
anticoagulants are also safe and effective in the treat-
ment of acute DVT.7,44,48,50,51
In this setting, we searched for and reviewed all ran-
domized trials that compared therapy with UFH ver-
sus a LMWH in patients suffering from VTE diag-
nosed by clinical examination or other objective and
valid diagnostic tests. Finally, a total of 4,472
patients were analyzed, thus including the highest
number of patients reported so far which substan-
tially increases the statistical power of the compar-
isons with respect to previous meta-analyses.
The results of this meta-analysis confirm previous
findings and indicate that LMWH preparations seem
to be more effective and safer than UFH for the treat-
ment of DVT.12-16 Some discordances between meta-
analyses and subsequent large-scale randomized trials
have been used to highlight the caution that must be
kept in mind when interpreting a meta-analysis.52,53
These caveats are always needed, and are relevant to
our study, too. Nevertheless, meta-analyses have sub-
stantial advantages, because they can give the best
available answer in each moment, can be useful to
estimate sample size for a definitive trial and may pro-
vide the most reliable treatment recommendation in
the situation of conflicting results from some of the tri-
als or in the absence of definitive trials.54
Although only a few of the individual studies ana-
lyzed showed a statistically significant improvement
in clot reduction in favor of LMWH when compared
with UFH,11,33-35 our meta-analysis shows that treat-
ment with LMWH can be more effective in reducing
thrombus size. Because thrombus extension may be
related to morbidity and mortality in these patients,
one of the short-term objectives for the treatment of
VTE is to prevent the extension of thrombus and thus
to avoid its sequealae, mainly post-phlebitic syn-
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Table 3. Separate comparisons between LMWH and UFH
depending on the number of doses of LMWH administered. 
LMWH vs UFH
Two doses Single dose χ2* p
[O.R. (95% CI)] [O.R. (95% CI)]
Clot reduction 0.56 (0.42-0.74) 1.08 (0.77-1.51) 8.56 0.004
Recurrence 0.74 (0.54-1.02) 1.00 (0.55-1.80) 0.74 0.390
Total mortality 0.74 (0.53-1.04) 0.50 (0.26-0.96) 1.08 0.300
Major bleeding 0.79 (0.47-1.32) 0.07 (0.01-0.54) 4.99 0.025
*Schlesseman chi-squared test for the comparison between ORs. LMWH: low
molecular weight heparin; UFH: unfractionated heparin; OR: odds ratio; CI:
confidence interval.
drome and thrombus recurrence. We can also spec-
ulate about the relationship between thrombus
extension and an increased embolic risk as Pollak55
previously suggested.
When efficacy of LMWH was assessed by compar-
ing the appearance of recurrent VTE we were unable
to find statistically significant differences between
treatment with LMWH and UFH. Although an
approximately 50% reduction in the relative risk of
recurrent venous thrombosis has been reported in the
meta-analysis of early trials of LMWH as compared
with UFH in the treatment of DVT,12,14,15 our findings
are inconsistent with a reduction of this magnitude
and more similar to results of other previous stud-
ies.13,16 However, the difference seen for this end-point
was also in favor of the LMWH in our study. Possibly
in the future new and more potent meta-analyses
(including new comparative works and thus a higher
number of patients) will reach a statistically signifi-
cant  difference in favor of LMWH.
When taken separately, only the study by Hull et
al.10 showed a statistically significant difference in
mortality between the two treatments. However, the
significant reduction in mortality in the LMWH group
shown in our study is consistent with the results of a
similar meta-analysis reported previously.14,15
Although mortality might be a pertinent end-point
for evaluating the efficacy of an antithrombotic drug,
death in patients with VTE usually occurs after the ini-
tial treatment period. Moreover, very few deaths of
those reported in the studies analyzed are due to fatal
PE, which supports the hypothesis proposed by
Douketis et al.56 that fatal PE is a rare event in patients
who have correctly followed anticoagulant treatment.
So, mortality within the first months seems to be
related to underlying diseases. In this setting,
although not adding new data to this issue, we agree
with other authors who suggest that malignant dis-
ease may explain many of the deaths in the studies,
as cancer is an important risk factor for VTE and
many patients in the trials analyzed had an oncolog-
ic disease.10,34 The cause of the reduced mortality in
cancer patients treated with LMWH is therefore a
both intriguing and difficult finding to explain. We
can hypothesize that anti-tumor growth factor activ-
ity or suppression of angiogenesis could be induced
more effectively by LMWH than by UFH.57,58 Never-
theless, further confirmation in prospective random-
ized trials is required.
Severe bleeding is an important concern when
studying the efficacy and safety of an anticoagulant
therapy. Although, of all the studies analyzed, only
one study10 showed a significant difference in the
rates of major bleeding between treatment groups,
when pooled together by means of the meta-analy-
sis, the studies showed that the use of LMWH pro-
duced a statistically significant lower incidence of
major bleeding. It is important to note that this
reduction in the rate of major hemorrhage when the
treatment was with LMWH was not at the cost of
decreasing the efficacy of the anticoagulation regi-
men.
Recent studies have demonstrated the possibility
and the advantages of outpatient administration of
LMWH.40,41,59,60 However, little is known about the
results of the comparison between the patients given
LMWH in two doses or as a single dose. With regard
to this point, although LMWH given as two doses was
better in decreasing phlebographic changes, treat-
ment as a single dose was equally effective in terms of
preventing recurrence and total mortality, and achiev-
ing a statistically significant reduction in major hem-
orrhage. Thus, our results further substantiate the
concept that the effects of a single dose of LMWH
could be as efficient as and safer than the two-dose
regimen, which would facilitate the outpatient treat-
ment of VTE proposed by other authors.40,41
We, therefore, conclude that LMWH is superior in
terms of safety and efficacy when compared with
UFH in unselected patients with DVT. Moreover,
LMWH regimes have several practical advantages.
They are more comfortable for patients, less time
consuming for nurses and produce less work for lab-
oratories. In addition, the fact that the single dose of
LMWH is a suitable therapeutic regimen would facil-
itate the outpatient treatment of VTE.
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